CA2067653C - Modified complement system regulator - Google Patents
Modified complement system regulator Download PDFInfo
- Publication number
- CA2067653C CA2067653C CA002067653A CA2067653A CA2067653C CA 2067653 C CA2067653 C CA 2067653C CA 002067653 A CA002067653 A CA 002067653A CA 2067653 A CA2067653 A CA 2067653A CA 2067653 C CA2067653 C CA 2067653C
- Authority
- CA
- Canada
- Prior art keywords
- protein
- amino acid
- amino acids
- analog
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000004154 complement system Effects 0.000 title description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 188
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 184
- 150000001413 amino acids Chemical group 0.000 claims abstract description 166
- 230000027455 binding Effects 0.000 claims abstract description 164
- 230000000694 effects Effects 0.000 claims abstract description 34
- 230000024203 complement activation Effects 0.000 claims abstract description 10
- 230000000295 complement effect Effects 0.000 claims description 55
- 230000001105 regulatory effect Effects 0.000 claims description 46
- 102000050019 Membrane Cofactor Human genes 0.000 claims description 45
- 101710146216 Membrane cofactor protein Proteins 0.000 claims description 45
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 42
- 238000006467 substitution reaction Methods 0.000 claims description 35
- 102000016550 Complement Factor H Human genes 0.000 claims description 29
- 108010053085 Complement Factor H Proteins 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- 102000011412 Complement 3d Receptors Human genes 0.000 claims description 15
- 108010023729 Complement 3d Receptors Proteins 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 102000000989 Complement System Proteins Human genes 0.000 claims description 7
- 108010069112 Complement System Proteins Proteins 0.000 claims description 7
- 108020004414 DNA Proteins 0.000 claims description 7
- 108091008324 binding proteins Proteins 0.000 claims description 7
- 102000006834 complement receptors Human genes 0.000 claims description 7
- 108010047295 complement receptors Proteins 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 108010009575 CD55 Antigens Proteins 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 2
- 230000009918 complex formation Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 102000023732 binding proteins Human genes 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 description 115
- 235000001014 amino acid Nutrition 0.000 description 109
- 230000037361 pathway Effects 0.000 description 30
- 230000004048 modification Effects 0.000 description 20
- 238000012986 modification Methods 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 19
- 238000010494 dissociation reaction Methods 0.000 description 18
- 230000005593 dissociations Effects 0.000 description 18
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 16
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 description 16
- 239000005515 coenzyme Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 11
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 11
- 101100365087 Arabidopsis thaliana SCRA gene Proteins 0.000 description 10
- 101150105073 SCR1 gene Proteins 0.000 description 10
- 101100134054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NTG1 gene Proteins 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000009261 transgenic effect Effects 0.000 description 8
- 230000004075 alteration Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 239000004074 complement inhibitor Substances 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 229940124073 Complement inhibitor Drugs 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- -1 and less directly Proteins 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000002427 irreversible effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 229930186217 Glycolipid Natural products 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 108091008053 gene clusters Proteins 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010078804 Classical Pathway Complement C5 Convertase Proteins 0.000 description 2
- 101100007625 Homo sapiens CR1 gene Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101150039984 RCA gene Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 2
- 208000024248 Vascular System injury Diseases 0.000 description 2
- 208000012339 Vascular injury Diseases 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 108010003529 Alternative Pathway Complement C3 Convertase Proteins 0.000 description 1
- 108010083822 Alternative Pathway Complement C5 Convertase Proteins 0.000 description 1
- 208000000104 Arthus reaction Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000015612 Complement 3b Receptors Human genes 0.000 description 1
- 108010024114 Complement 3b Receptors Proteins 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100386242 Homo sapiens CD55 gene Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 108010052926 complement C3d,g Proteins 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009146 cooperative binding Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000016178 immune complex formation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000031978 negative regulation of complement activation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69551491A | 1991-05-03 | 1991-05-03 | |
| US695,514 | 1991-05-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2067653A1 CA2067653A1 (en) | 1992-11-04 |
| CA2067653C true CA2067653C (en) | 2001-02-13 |
Family
ID=24793320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002067653A Expired - Fee Related CA2067653C (en) | 1991-05-03 | 1992-04-30 | Modified complement system regulator |
Country Status (5)
| Country | Link |
|---|---|
| US (6) | US6897290B1 (enFirst) |
| EP (2) | EP0512733A2 (enFirst) |
| JP (1) | JP2793431B2 (enFirst) |
| AU (1) | AU657751B2 (enFirst) |
| CA (1) | CA2067653C (enFirst) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6482404B1 (en) | 1989-10-12 | 2002-11-19 | David James White | Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor |
| EP0512733A2 (en) | 1991-05-03 | 1992-11-11 | Washington University | Modified complement system regulator |
| WO1994026786A1 (en) | 1993-05-17 | 1994-11-24 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
| US5976540A (en) * | 1993-05-17 | 1999-11-02 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
| US5856300A (en) * | 1994-05-12 | 1999-01-05 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
| EP1493446A1 (en) * | 1993-09-24 | 2005-01-05 | Washington University | Modified truncated complement system regulators |
| CA2171953C (en) * | 1993-09-24 | 2003-02-04 | John P. Atkinson | Modified truncated complement system regulators |
| US5679546A (en) * | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| US5866402A (en) * | 1995-05-05 | 1999-02-02 | Chiron Corporation | Chimeric MCP and DAF proteins with cell surface localizing domain |
| GB9604518D0 (en) * | 1996-03-02 | 1996-05-01 | Smithkline Beecham Plc | Novel compounds |
| GB9624731D0 (en) * | 1996-11-28 | 1997-01-15 | Univ Leicester | Complement inhibitor |
| GB9704519D0 (en) | 1997-03-05 | 1997-04-23 | Smithkline Beecham Plc | Compounds |
| US6221621B1 (en) | 1997-03-06 | 2001-04-24 | Bard Diagnostic Sciences, Inc. | Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated |
| EP0972200A1 (en) * | 1997-03-06 | 2000-01-19 | Bion Diagnostic Sciences, Inc. | Screening and treatment using complement regulator or receptor proteins |
| WO2000061752A2 (en) * | 1999-04-09 | 2000-10-19 | Washington University | Modified complement system regulators |
| US20090054330A1 (en) * | 1999-05-25 | 2009-02-26 | Kotwal Girish J | Novel Therapeutic Use of Viral Inflammation Modulatory Protein in Blocking Xenograft Rejection |
| DE60022499T2 (de) * | 1999-05-25 | 2006-11-30 | King Faisal Specialist Hospital And Research Centre | Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten |
| US6820011B2 (en) * | 2001-04-11 | 2004-11-16 | The Regents Of The University Of Colorado | Three-dimensional structure of complement receptor type 2 and uses thereof |
| JP2004529945A (ja) * | 2001-05-17 | 2004-09-30 | ラ ホヤ ファーマシューティカル カンパニー | Ｃｄ２１を阻害する薬剤を使用して抗体媒介性病理を処置する方法 |
| ES2392511T3 (es) * | 2002-11-15 | 2012-12-11 | Musc Foundation For Research Development | Moduladores de complemento dianas sobre el receptor 2 de complemento |
| DE10343620A1 (de) * | 2003-09-20 | 2005-04-28 | Leibrock Maschinenfabrik Im Un | Verfahren und Vorrichtung zum Erfassen der zum Rauen bestimmten Seitenbereiche von auf Leisten aufgebrachten Schuhschäften |
| WO2005069726A2 (en) * | 2004-01-21 | 2005-08-04 | Case Western Reserve University | Hybrid and chimeric polypeptides that regulate activation of complement |
| ES2432112T3 (es) * | 2004-02-10 | 2013-11-29 | The Regents Of The University Of Colorado, A Body Corporate | Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados |
| US7947267B2 (en) * | 2004-10-08 | 2011-05-24 | Potentia Pharmaceuticals, Inc. | Viral complement control proteins for eye disorders |
| US8043609B2 (en) | 2004-10-08 | 2011-10-25 | Potentia Pharmaceuticals, Inc. | Viral complement control proteins for eye disorders |
| AU2006249835B2 (en) * | 2005-05-26 | 2011-09-08 | Musc Foundation For Research Development | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
| EP1738763A1 (en) * | 2005-06-30 | 2007-01-03 | AVANT Immunotherapeutics, Inc. | Use of complement inhibitory proteins to treat spinal cord injury |
| US20070004625A1 (en) * | 2005-06-30 | 2007-01-04 | Li Liang-Man | Use of complement inhibitory proteins to treat spinal cord injury |
| AU2006302212B2 (en) | 2005-10-08 | 2012-12-20 | Apellis Pharmaceuticals, Inc. | Compstatin and analogs thereof for eye disorders |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| EP2826788B1 (en) | 2006-06-21 | 2017-12-13 | MUSC Foundation for Research Development | Targeting complement factor h for treatment of diseases by the use of cr2-fh molecules |
| ATE551350T1 (de) | 2006-07-13 | 2012-04-15 | Univ Iowa Res Found | Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegeneration |
| US7964705B2 (en) | 2007-03-14 | 2011-06-21 | Taligen Therapeutics, Inc. | Humaneered anti-factor B antibody |
| US20110092446A1 (en) * | 2007-07-20 | 2011-04-21 | Cedric Francois | Compositions and methods for treatment of trauma |
| US20110190221A1 (en) * | 2008-03-28 | 2011-08-04 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| ME01699B (me) | 2009-07-02 | 2014-09-20 | Musc Found For Res Dev | Metode za stimulaciju regeneracije jetre |
| NZ600393A (en) | 2009-11-05 | 2014-08-29 | Alexion Cambridge Corp | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| BR112012029067A2 (pt) | 2010-05-14 | 2019-09-24 | Univ Colorado Regents | grupos-alvo de receptor do complemento 2 (cr2) melhorados. |
| US9421240B2 (en) | 2010-06-22 | 2016-08-23 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| MX2012014975A (es) | 2010-06-22 | 2013-03-12 | Univ Colorado Regents | Anticuerpos al fragmento c3d de componente 3 de complemento. |
| BR112013005116A2 (pt) | 2010-09-03 | 2019-09-24 | Stem Centrx Inc | moduladores e métodos de uso |
| US20120148542A1 (en) | 2010-12-10 | 2012-06-14 | Lifeline Scientific, Inc. | Machine perfusion with complement inhibitors |
| WO2012155107A1 (en) | 2011-05-11 | 2012-11-15 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
| MX379206B (es) | 2011-06-22 | 2025-03-10 | Apellis Pharmaceuticals Inc | Uso de inhibidores del complemento en trastornos crónicos. |
| EP2557089A2 (en) * | 2011-07-15 | 2013-02-13 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compositions and methods for immunomodulation |
| EP2855529A4 (en) | 2012-05-24 | 2015-12-09 | Alexion Pharma Inc | HUMANIZED ANTI-FACTOR B ANTIBODIES |
| AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| EP3929206A1 (en) | 2012-11-15 | 2021-12-29 | Apellis Pharmaceuticals, Inc. | Long-acting compstatin analogs and related compositions and methods |
| US10308687B2 (en) | 2013-03-15 | 2019-06-04 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| WO2016094834A2 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | A method for treating a complement mediated disorder caused by an infectious agent in a patient |
| WO2017044811A1 (en) | 2015-09-11 | 2017-03-16 | Bruce Andrien | Recombinant glycosylated eculizumab and eculizumab variants |
| EP3359566A1 (en) | 2015-10-07 | 2018-08-15 | Alexion Pharmaceuticals, Inc. | A method for treating age-related macular degeneration in a patient |
| MX392574B (es) | 2015-10-07 | 2025-03-24 | Apellis Pharmaceuticals Inc | Análogos de compstatina de acción prolongada para usarse en el tratamiento de trastornos oculares |
| MX2019000059A (es) * | 2016-06-28 | 2020-09-07 | Univ Ulm | Inhibidores de complementos y usos de los mismos. |
| WO2018075761A1 (en) | 2016-10-19 | 2018-04-26 | Alexion Pharmaceuticals, Inc. | A method of quantitating unbound c5a in a sample |
| US11965884B2 (en) | 2016-10-19 | 2024-04-23 | Alexion Pharmaceuticals, Inc. | Method of quantitating unbound C5 in a sample |
| CN116059313A (zh) | 2017-04-07 | 2023-05-05 | 阿佩利斯制药有限公司 | 给药方案以及相关组合物和方法 |
| JP2021507884A (ja) | 2017-12-15 | 2021-02-25 | アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 投与レジメンならびに関連組成物および方法 |
| US20220220169A1 (en) | 2019-05-15 | 2022-07-14 | Insideoutbio, Inc. | Modular Therapeutics for the Treatment of Inflammatory Diseases and Cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212071A (en) | 1988-04-01 | 1993-05-18 | The Johns Hopkins University | Nucleic acids encoding a human C3b/C4b receptor (CR1) |
| US5109113A (en) * | 1986-05-02 | 1992-04-28 | Genentech, Inc. | Membrane anchor fusion polypeptides |
| JPH0742235B2 (ja) * | 1985-11-08 | 1995-05-10 | 三共株式会社 | 自己免疫性疾病の予防・治療剤 |
| US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| IL89790A (en) | 1988-04-01 | 2002-05-23 | Johns Hopking University | Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification |
| US5256642A (en) * | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
| JP2750220B2 (ja) * | 1989-07-21 | 1998-05-13 | ワシントン ユニバーシティ | 組換え産生したヒト細胞膜補助因子タンパク（ｍｃｐ） |
| AU655182B2 (en) * | 1990-05-11 | 1994-12-08 | Austin Research Institute, The | CD46 variants |
| EP0537171B1 (en) * | 1990-05-11 | 2002-09-18 | The Austin Research Institute | CD46 isoforms |
| EP0512733A2 (en) * | 1991-05-03 | 1992-11-11 | Washington University | Modified complement system regulator |
| JPH05271288A (ja) | 1992-02-21 | 1993-10-19 | Mochida Pharmaceut Co Ltd | 新規な薬理学的特性を有する蛋白質 |
-
1992
- 1992-04-28 EP EP92303826A patent/EP0512733A2/en not_active Ceased
- 1992-04-28 EP EP20030024658 patent/EP1413587A2/en not_active Withdrawn
- 1992-04-29 AU AU15902/92A patent/AU657751B2/en not_active Ceased
- 1992-04-30 CA CA002067653A patent/CA2067653C/en not_active Expired - Fee Related
- 1992-05-06 JP JP4113457A patent/JP2793431B2/ja not_active Expired - Fee Related
-
1993
- 1993-09-24 US US08/126,505 patent/US6897290B1/en not_active Expired - Fee Related
-
1994
- 1994-03-18 US US08/210,266 patent/US5545619A/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/477,860 patent/US6010873A/en not_active Expired - Fee Related
-
1996
- 1996-07-30 US US08/688,675 patent/US5719127A/en not_active Expired - Fee Related
-
1999
- 1999-12-02 US US09/453,835 patent/US6521450B1/en not_active Expired - Lifetime
-
2004
- 2004-11-23 US US10/997,454 patent/US20080119400A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1413587A2 (en) | 2004-04-28 |
| AU657751B2 (en) | 1995-03-23 |
| US6521450B1 (en) | 2003-02-18 |
| US6010873A (en) | 2000-01-04 |
| US5545619A (en) | 1996-08-13 |
| CA2067653A1 (en) | 1992-11-04 |
| EP0512733A3 (enFirst) | 1994-08-03 |
| US5719127A (en) | 1998-02-17 |
| JPH0616696A (ja) | 1994-01-25 |
| US20080119400A1 (en) | 2008-05-22 |
| EP0512733A2 (en) | 1992-11-11 |
| JP2793431B2 (ja) | 1998-09-03 |
| US6897290B1 (en) | 2005-05-24 |
| AU1590292A (en) | 1992-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2067653C (en) | Modified complement system regulator | |
| Edery et al. | Identification and sequence analysis of a second form of prolactin receptor by molecular cloning of complementary DNA from rabbit mammary gland. | |
| Alloisio et al. | Evidence that red blood cell protein p55 may participate in the skeleton-membrane linkage that involves protein 4.1 and glycophorin C | |
| Ehlers et al. | Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme. | |
| US6458360B1 (en) | Soluble complement regulatory molecules | |
| JP3492999B2 (ja) | 脂肪細胞特異的タンパク質の同族体 | |
| ES2300114T3 (es) | Polipeptidos de fusion que comprenden un dominio de enlazamiento de ige y un componente de hsa, y sus usos diagnosticos y terapeuticos. | |
| EP1104466A1 (en) | Leptin-related peptides | |
| JPH022351A (ja) | インターロイキン―１受容体 | |
| KR19980703061A (ko) | Ｉｌ-17 수용체 | |
| US5663070A (en) | Recombinant production of a soluble splice variant of the Fas (Apo-1) antigen, fas TM | |
| KR100385868B1 (ko) | 함지방세포-특이적 단백질 상동체 | |
| US7807783B1 (en) | Methods and compositions for regulating FAS-associated apoptosis | |
| US6083688A (en) | Platelet glycoprotein V gene and uses | |
| US20060079668A1 (en) | Junctional adhesion molecule splice variants | |
| EP0730469B1 (en) | Modified truncated complement system regulators | |
| Kiang et al. | Identification and characterization of Schistosoma mansoni p17. 7, a cyclophilin | |
| US6060238A (en) | Method and composition for regulating apoptosis | |
| CA2046925A1 (en) | Pregnancy specific proteins applications | |
| CA2494706A1 (en) | Chimeric glycosylphosphatidylinositol containing peptides | |
| HK1065552A (en) | Modified complement system regulator | |
| WO2000061752A2 (en) | Modified complement system regulators | |
| Tejada et al. | Cloning of an avian antithrombin: developmental and hormonal regulation of expression | |
| EP1493446A1 (en) | Modified truncated complement system regulators | |
| Palacín | The family of heteromultimeric amino acid transporters reveals aminoaciduria genes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |